31/01/2015 12:54:21 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
01/30/20151:04PMDJNEli Lilly Sales Hit by Patent Expirations, Currency
By Michael Calia Eli Lilly and Co. said Friday foreign-exchange pressures weighed on sales in the most recent quarter as the pharmaceutical company continued to suffer the impact of patent expirations on some of its key drugs. The company, citing the stronger U.S. dollar, adjusted its outlook for the year, including reducing... More...>>
01/29/20155:19PMBWU.S. Food & Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir & cobicistat) for the Treatment of HI...
Evotaz is the first and only protease inhibitor pharmacoenhanced by cobicistat that is supported by comparative Phase III clinical trial data Evotaz is the only protease inhibitor pharmacoenhanced by cobicistat with virologic failure rates as low as 6% [HIV-1 RNA ≥50 copies/mL at 48 weeks: 6% Evotaz arm; 4% Reyataz®(atazanavir)/ritonavir... More...>>
01/29/20158:00AMGLOBECelldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) ...
HAMPTON, N.J., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational immune-activating... More...>>
01/27/20152:18PMDJNBristol-Myers Sales Boosted by Cancer Drugs -- Update
By Tess Stynes And Jonathan D. Rockoff Bristol-Myers Squibb Co. reported better-than-expected fourth-quarter revenue, boosted by robust sales of its key drugs and a stronger dollar. Bristol reported a profit of $13 million, or a penny a share, down from $726 million, or 44 cents a share, a year earlier. Excluding a pension-related... More...>>
01/27/20151:12PMDJNBristol-Myers Sales Boosted by Cancer Drugs
By Tess Stynes Bristol-Myers Squibb Co. reported stronger-than-expected fourth-quarter revenue, boosted by strong sales of its key drugs and despite a hit from the divestiture of its diabetes business last year and impacts from a stronger dollar. The drug maker is poised for a management shift as the leaders who transformed... More...>>
01/27/20157:30AMBWBristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results
Achieves Accelerated U.S. Regulatory Approval for Opdivo in Metastatic Melanoma Announces Early Stop of CheckMate -017, a Phase 3 Study of Opdivo, After Data Demonstrates Superior Overall Survival Posts Fourth Quarter GAAP EPS of $0.01 and Non-GAAP EPS of $0.46 Provides 2015 GAAP and Non-GAAP EPS Guidance Range of $1.55... More...>>
01/20/20156:48PMDJNBristol-Myers Operating Chief to Become CEO in May -- 2nd Update
By Jonathan D. Rockoff Bristol-Myers Squibb Co. said Tuesday that Chief Operating Officer Giovanni Caforio will become its next chief executive, as the leaders who turned the pharmaceutical company into an immunotherapy powerhouse exit. Dr. Caforio, 50, will succeed 64-year-old Lamberto Andreotti, effective May 5. Mr... More...>>
01/20/20155:55PMDJNBristol-Myers Operating Chief to Become CEO in May -- Update
By Josh Beckerman Bristol-Myers Squibb Co. said Giovanni Caforio will succeed Lamberto Andreotti as chief executive in May. Mr. Andreotti, 64, will become executive chairman in May and will remain chairman after his retirement in August. Mr. Caforio, 50, joined the company in 2000 and was named chief operating officer... More...>>
01/20/20155:23PMDJNBristol-Myers Operating Chief to Become CEO in May
By Josh Beckerman Bristol-Myers Squibb Co. said Giovanni Caforio will succeed Lamberto Andreotti as chief executive in May. Mr. Andreotti, 64, will become executive chairman in May and will remain chairman after his retirement in August. Mr. Caforio, 50, joined the company in 2000 and was named chief operating officer... More...>>
01/20/20154:30PMBWBristol-Myers Squibb Appoints Giovanni Caforio, M.D., Chief Executive Officer, Effective May 5; Lamberto Andreotti to Become ...
Bristol-Myers Squibb Company (NYSE:BMY) today announced a number of leadership changes approved by its board of directors and effective at the close of the annual Shareholders’ Meeting on May 5. Giovanni Caforio, M.D. (Photo: Business Wire) Giovanni Caforio, M.D., 50, will become chief executive officer of the company... More...>>
01/17/20159:09PMDJNInvesting for the Long Term
By Gregory Zuckerman Investors often try to profit by betting on short- and medium-term shifts in stocks and bonds. But the real money comes from anticipating long-term trends, the kinds of changes that take place over many years. That's why some experts encourage investors to focus on shifts that may develop over the... More...>>
01/13/20158:00AMBWBristol-Myers Squibb & Lilly Enter Clinical Collaboration Agreement to Evaluate Opdivo (nivolumab) in Combination with Galuni...
Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) announced today a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) in combination with Lilly’s galunisertib (LY2157299). The Phase 1/2 trial... More...>>
01/12/20156:56PMDJNU.S. Stock Futures Increase After 2 Losing Weeks
By Saumya Vaishampayan U.S. stocks were poised for a higher open Monday, following two straight weeks of losses. Gains in European stocks and deal news helped lift stocks in premarket trade. Dow Jones Industrial Average futures rose 59 points, or 0.3%, to 17708. S&P 500 futures gained seven points, or 0.4%, to 2042... More...>>
01/12/20158:00AMBWSeattle Genetics & Bristol-Myers Squibb Announce Clinical Collaboration to Evaluate Combination of Adcetris® (Brentuximab Ve...
Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that the companies have entered into a clinical trial collaboration agreement to evaluate the investigational combination of Seattle Genetics’ antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin) and Bristol-Myers... More...>>
01/11/20159:06PMBWCheckMate -017, A Phase 3 Study of Opdivo (Nivolumab) Compared to Docetaxel in Patients with Second-Line Squamous Cell Non-sm...
Opdivo demonstrates superior overall survival in this Phase 3 trial Bristol-Myers Squibb Company (NYSE:BMY) today announced that an open-label, randomized Phase 3 study evaluating Opdivo versus docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer (NSCLC) was stopped early because... More...>>
01/06/20159:30AMBWBristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015, in San Francisco. Giovanni Caforio, chief operating officer, will make a formal presentation about the company at 9 a.m. PST (12 p.m. EST). Investors and the general public are invited to listen to... More...>>
01/05/20158:00AMBWBristol-Myers Squibb & California Institute for Biomedical Research (Calibr) Sign Worldwide Research Collaboration & License ...
Bristol-Myers Squibb Company (NYSE:BMY) and the California Institute for Biomedical Research (Calibr) announced today they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture... More...>>
12/22/20145:21PMBWBristol-Myers Squibb Receives Accelerated Approval of Opdivo (nivolumab) from the U.S. Food and Drug Administration
First approval of Opdivo in the United States Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab) injection, for intravenous use. Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients... More...>>
12/22/20143:11PMBWBristol-Myers Squibb Announces U.S. FDA Approval of Opdivo (nivolumab)
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab). Please see full Prescribing Information available at www.bms.com. The company will provide additional details on the approval in a press release to follow. About Bristol-Myers Squibb... More...>>
12/17/201410:00AMBWBristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2014 on January 27
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter and full year of 2014 on Tuesday, January 27, 2015. During a conference call at 9 a.m. EST on January 27, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy150131 12:54